Johane Boucher-Champagne, executive vice president, early clinical development of PharmaNet Development Group, has been appointed president and chief executive officer of the company’s subsidiary, Anapharm, Inc., effective March 18, 2007. Ms. Boucher-Champagne will report to Mark Di Ianni, the company’s president of early stage operations.

“Johane provided valuable assistance during the transition of the early stage business during the past year,” commented Mark Di Ianni. “Her energy, integrity and leadership skills have been demonstrated over the many years that she has contributed to the growth and development of Anapharm.”

Ms. Boucher-Champagne was appointed to her most recent position at PharmaNet in March 2006, where she provided senior leadership on global phase I and early stage business development. She has been serving as acting president and chief executive officer of Anapharm since December 2006. Previously, she served as chief operating officer of Anapharm.

Also, Dr. Marc LeBel will be leaving the company on March 18, 2007. He has served as president and chief executive officer of Anapharm since March 2002 and has held the position of executive vice president, bioanalytical laboratories, PharmaNet Development Group, since March 2006.